Koers Kuros Biosciences AG Swiss Exchange
Aandelen
CH0325814116
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 17,99 mln. 19,84 mln. 18,41 mln. | Omzet 2023 | 33,56 mln. 37,02 mln. 34,35 mln. | Marktkapitalisatie | 128 mln. 142 mln. 131 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -14 mln. -15,44 mln. -14,33 mln. | Nettowinst (verlies) 2023 | -13 mln. -14,34 mln. -13,3 mln. | EV/omzet 2022 | 1,76 x |
Nettoliquiditeiten 2022 | 22,08 mln. 24,36 mln. 22,6 mln. | Nettoliquiditeiten 2023 | 12 mln. 13,23 mln. 12,28 mln. | EV/omzet 2023 | 3,46 x |
K/w-verhouding 2022 |
-3,41
x | K/w-verhouding 2023 |
-9,18
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 64,77% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04-12-17 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19-04-21 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14-06-18 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19-04-21 |
Joost de Bruijn
FOU | Founder | 58 | 04-12-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,92% | 108 mld. | |
+10,19% | 105 mld. | |
+1,57% | 23,46 mld. | |
-12,38% | 21,72 mld. | |
-7,05% | 18,64 mld. | |
-37,64% | 17,45 mld. | |
-6,54% | 17,19 mld. | |
+6,14% | 13,99 mld. | |
+37,04% | 12,53 mld. |